Novo Nordisk A/S (NOVO-B.CO)

Copenhagen · Healthcare · Drug Manufacturers - General
264.50 DKK-0.25%As of 2026-11-22 · DKK
Last session low 260.35 DKKLast session high 266.15 DKK
52-week low 224.25 DKK52-week high 409.95 DKK
Market cap (USD)
$171.08B
Sector
Healthcare
P/E (TTM)
10.4x
Dividend yield
4.42%
Next earnings
2027-02-03

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in DKK.

IndicatorValueReading
RSI (14)45.7In the neutral range (30 to 70)
MACD (12, 26, 9)1.83Below its signal line (2.69); histogram -0.86
Bollinger %B (20, 2)32%Inside the bands (254.47 to 285.59)
SMA 20270.03Price is 2.0% below
SMA 50263.42Price is 0.4% above
SMA 200275.82Price is 4.1% below
ATR (20)3.27% of priceAverage true range per day
52-week position22%In the lower part of the 224.25 to 409.95 range

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Latest fiscal yearEnded 2025-12-31: revenue of 309.06B DKK and an operating margin of 41.3%.
Next earnings reportExpected on 2027-02-03.

Also listed as NOV.DE (XETRA), NVO (NYSE)

More in Drug Manufacturers - General